JP2010516763A - 感染性病原体又は毒素に関連する疾患のためのワクチンアジュバントとしての細胞外マトリックス物質 - Google Patents

感染性病原体又は毒素に関連する疾患のためのワクチンアジュバントとしての細胞外マトリックス物質 Download PDF

Info

Publication number
JP2010516763A
JP2010516763A JP2009547231A JP2009547231A JP2010516763A JP 2010516763 A JP2010516763 A JP 2010516763A JP 2009547231 A JP2009547231 A JP 2009547231A JP 2009547231 A JP2009547231 A JP 2009547231A JP 2010516763 A JP2010516763 A JP 2010516763A
Authority
JP
Japan
Prior art keywords
vaccine
extracellular matrix
adjuvant
infectious
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009547231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516763A5 (enExample
Inventor
マーク・エー・サッコー
ウィリアム・アール・ウォルター
ポール・ホール
Original Assignee
ユニバーシティ オブ ノートル ダム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ノートル ダム filed Critical ユニバーシティ オブ ノートル ダム
Publication of JP2010516763A publication Critical patent/JP2010516763A/ja
Publication of JP2010516763A5 publication Critical patent/JP2010516763A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2009547231A 2007-01-30 2007-05-25 感染性病原体又は毒素に関連する疾患のためのワクチンアジュバントとしての細胞外マトリックス物質 Pending JP2010516763A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/699,448 US9308252B2 (en) 2005-10-27 2007-01-30 Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
PCT/US2007/069727 WO2008094276A1 (en) 2007-01-30 2007-05-25 Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins

Publications (2)

Publication Number Publication Date
JP2010516763A true JP2010516763A (ja) 2010-05-20
JP2010516763A5 JP2010516763A5 (enExample) 2012-11-22

Family

ID=39359947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009547231A Pending JP2010516763A (ja) 2007-01-30 2007-05-25 感染性病原体又は毒素に関連する疾患のためのワクチンアジュバントとしての細胞外マトリックス物質

Country Status (6)

Country Link
US (3) US9308252B2 (enExample)
EP (1) EP2114444B1 (enExample)
JP (1) JP2010516763A (enExample)
CN (1) CN101730541B (enExample)
AU (1) AU2007345673A1 (enExample)
WO (2) WO2008094276A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US9308252B2 (en) 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP3058954B1 (en) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
ES2552858T3 (es) 2007-10-01 2015-12-02 Longhorn Vaccines And Diagnostics, Llc Recogida de muestras biológicas y sistema de transporte y métodos de uso
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
WO2010078478A1 (en) 2008-12-31 2010-07-08 Cook Biotech Incorporated Tissue adjuvants and medical products including the same
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
EP3494989B1 (en) 2012-01-26 2025-07-16 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
CA2879066C (en) * 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
CA2879023C (en) 2012-07-13 2017-03-28 Wave Life Sciences Japan Asymmetric auxiliary group
CN103110943B (zh) * 2013-03-11 2014-11-26 浙江普康生物技术股份有限公司 一种可替代氢氧化铝的新型疫苗佐剂
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
CN106860861B (zh) * 2017-03-03 2020-11-03 北京博辉瑞进生物科技有限公司 一种免疫增强组合物、制备方法及其应用
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
CA3176187A1 (en) * 2020-04-22 2021-10-28 Clay Fette Compositions comprising extracellular material with antiviral activity and uses thereof
GB2615470A (en) 2020-10-20 2023-08-09 Longhorn Vaccines & Diagnostics Llc Immunogenic antigens
US20250375512A1 (en) * 2022-06-24 2025-12-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of matrix bound vesicles (mbv) as vaccine adjuvants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10513363A (ja) * 1995-02-10 1998-12-22 パーデュー・リサーチ・ファウンデーション 細胞の増殖基質としての粘膜下組織
US6264992B1 (en) * 1998-02-27 2001-07-24 Purdue Research Foundation Submucosa as a growth substrate for cells

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2172903A (en) 1937-09-24 1939-09-12 Paul M Charping Electric lighting system
US3346401A (en) 1963-12-12 1967-10-10 Council Scient Ind Res Processing of raw intestines
AT261800B (de) 1966-08-22 1968-05-10 Braun Internat Gmbh B Verfahren zur Herstellung von röhrenförmigen, glatten bzw. mit einem Gewinde versehenen Gewebe-Blutgefäß-Prothesen
US3810473A (en) 1972-12-04 1974-05-14 Avicon Inc Liquid-laid, non-woven, fibrous collagen derived surgical web having hemostatic and wound sealing properties
US4578067A (en) 1982-04-12 1986-03-25 Alcon (Puerto Rico) Inc. Hemostatic-adhesive, collagen dressing for severed biological surfaces
US4502159A (en) 1982-08-12 1985-03-05 Shiley Incorporated Tubular prostheses prepared from pericardial tissue
EP0331786B1 (de) 1988-03-11 1994-08-03 CHEMOKOL G.b.R. Ing.-Büro für Kollagenprodukte Verfahren zur Herstellung von Kollagenmembranen für Hämostase, Wundbehandlung und Implantate
US4902508A (en) 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US4956178A (en) 1988-07-11 1990-09-11 Purdue Research Foundation Tissue graft composition
US5837269A (en) 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US6120991A (en) * 1990-10-30 2000-09-19 Fred Hutchinson Cancer Research Center Epiligrin, an epithelial ligand for integrins
US5281422A (en) 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5507810A (en) 1991-10-07 1996-04-16 Osteotech, Inc. Processing of fibrous connective tissue
US5437287A (en) 1992-08-17 1995-08-01 Carbomedics, Inc. Sterilization of tissue implants using iodine
US5275826A (en) 1992-11-13 1994-01-04 Purdue Research Foundation Fluidized intestinal submucosa and its use as an injectable tissue graft
US5352463A (en) 1992-11-13 1994-10-04 Badylak Steven F Tissue graft for surgical reconstruction of a collagenous meniscus and method therefor
US5480424A (en) 1993-11-01 1996-01-02 Cox; James L. Heart valve replacement using flexible tubes
US5460962A (en) 1994-01-04 1995-10-24 Organogenesis Inc. Peracetic acid sterilization of collagen or collagenous tissue
US6156305A (en) 1994-07-08 2000-12-05 Baxter International Inc. Implanted tumor cells for the prevention and treatment of cancer
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US5554389A (en) 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
DE69622548T2 (de) * 1995-04-07 2003-09-18 Methodist Health Group, Inc. Gewebetransplantat zur blasenrekonstruktion
US5733337A (en) 1995-04-07 1998-03-31 Organogenesis, Inc. Tissue repair fabric
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
ES2206696T3 (es) 1996-04-03 2004-05-16 The Rogosin Institute Perlas de agarosa-colageno implantables que contienen celulas que producen un producto biologico difundible, y sus usos.
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
BR9711166A (pt) 1996-08-23 1999-08-17 Cook Biotech Inc PrÄtese de enxerto materiais para sua prepara-Æo e m-todos para seu uso
KR20000049096A (ko) 1996-10-11 2000-07-25 린다 에스. 스티븐슨 혼합 림프구와 조합된 종양세포를 사용하는 암 면역요법
US5782914A (en) 1996-11-29 1998-07-21 Bio-Vascular, Inc. Method for preparing heterogeneous tissue grafts
ES2227833T3 (es) 1997-05-12 2005-04-01 Aphton Corporation Composiciones inmunogenicas para el receptor cck-b/gastrina y metodos para el tratamiento de tumores.
DE19916085A1 (de) * 1998-10-28 2000-05-04 Sonntag Hans Guenther Verfahren zur Herstellung eines antiviralen Mittels
GB9827103D0 (en) 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
JP2000264900A (ja) 1999-03-16 2000-09-26 Hisamitsu Pharmaceut Co Inc 新規生理活性ペプチド
CA2367922A1 (en) 1999-03-16 2000-10-05 Thomas Jefferson University Hapten-conjugated mammalian cells and methods of making and using thereof
US6105775A (en) * 1999-04-20 2000-08-22 Pakon, Inc. Sleeving system for photographic film negatives
AU4661900A (en) 1999-04-26 2000-11-10 Emory University Noscapine derivatives as adjuvant compositions and methods of use thereof
US7015205B1 (en) 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
IT1318663B1 (it) 2000-08-02 2003-08-27 Mediolanum Farmaceutici Srl Membrane di collagene a due facce di cui una organizzata a livellomacromolecolare.
US7087089B2 (en) * 2001-06-28 2006-08-08 Cook Biotech Incorporated Graft prosthesis devices containing renal capsule collagen
AU2002324775A1 (en) * 2001-08-23 2003-03-10 Sciperio, Inc. Architecture tool and methods of use
AU2003265229A1 (en) 2002-03-18 2003-12-12 Sciperio, Inc. Dentritic cell nodes
FR2842822B1 (fr) 2002-07-26 2004-10-01 Roussy Inst Gustave Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales
US7175652B2 (en) 2002-08-20 2007-02-13 Cook Incorporated Stent graft with improved proximal end
US7550004B2 (en) 2002-08-20 2009-06-23 Cook Biotech Incorporated Endoluminal device with extracellular matrix material and methods
AU2004270239C1 (en) * 2003-09-04 2011-07-07 Cook Biotech Incorporated Extracellular matrix composite materials, and manufacture and use thereof
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
EP1887980B1 (en) 2005-05-17 2012-09-05 Cook Medical Technologies LLC Frameless valve prosthesis and system for its deployment
EP1996013A4 (en) * 2005-09-21 2010-03-10 Dask Technologies Llc METHODS AND COMPOSITIONS FOR FUNCTIONALITY OF ORGANS AND TISSUES
US8802113B2 (en) 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778360B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US7545569B2 (en) * 2006-01-13 2009-06-09 Avery Dennison Corporation Optical apparatus with flipped compound prism structures
CA2627364A1 (en) 2007-01-30 2008-07-30 University Of Notre Dame Du Lac Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US9283266B2 (en) 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10513363A (ja) * 1995-02-10 1998-12-22 パーデュー・リサーチ・ファウンデーション 細胞の増殖基質としての粘膜下組織
US6264992B1 (en) * 1998-02-27 2001-07-24 Purdue Research Foundation Submucosa as a growth substrate for cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012033652; Ｖａｃｃｉｎｅ．　１９［２３-２４］　（２００１）　ｐ．３０９１-６． *
JPN6012033655; Ｊ　Ｂｉｏｍａｔｅｒ　Ｓｃｉ　Ｐｏｌｙｍｅｒ　Ｅｄｎ．，　９［８］　（１９９８）　ｐ．８６３-８． *
JPN6012033656; Ｖａｃｃｉｎｅ．　１３［７］　（１９９５）　ｐ．６５３-６１． *
JPN6012033658; Ｊ　Ｂｉｏｍｅｄ　Ｍａｔｅｒ　Ｒｅｓ．，　６７Ａ　（１２００３）　ｐ．６３７-４０． *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US9308252B2 (en) 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins

Also Published As

Publication number Publication date
WO2008112344A3 (en) 2009-12-30
WO2008094276A1 (en) 2008-08-07
AU2007345673A1 (en) 2008-08-07
US9308252B2 (en) 2016-04-12
US20080107665A1 (en) 2008-05-08
US9220770B2 (en) 2015-12-29
EP2114444A4 (en) 2010-09-29
CN101730541B (zh) 2014-03-05
CN101730541A (zh) 2010-06-09
WO2008112344A2 (en) 2008-09-18
EP2114444A1 (en) 2009-11-11
US20110076305A1 (en) 2011-03-31
US20100136050A1 (en) 2010-06-03
EP2114444B1 (en) 2014-10-22

Similar Documents

Publication Publication Date Title
JP2010516763A (ja) 感染性病原体又は毒素に関連する疾患のためのワクチンアジュバントとしての細胞外マトリックス物質
Shah et al. Overview of vaccine adjuvants: introduction, history, and current status
ES2331952T3 (es) Fraccion de quil a con baja toxicidad y su uso.
Sokolova et al. The potential of nanoparticles for the immunization against viral infections
JP2011190278A (ja) 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方
US20130089570A1 (en) Oral vaccine compromising an antigen and a toll-like receptor agonist
US9585955B2 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
BE1022008B1 (fr) Compositions immunogenes combinees
EP2879704A1 (en) Method for eliciting in infants an immune response against rsv and b. pertussis
US20140322271A1 (en) Vaccine comprising a tlr-5 agonist as adjuvant for use in cutaneous immunisation
CN102470168A (zh) 新组合物
WO2014024026A1 (en) Method for eliciting in infants an immune response against rsv and b. pertussis
CA2627364A1 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US20250057940A1 (en) Immune memory enhanced preparations and uses thereof
US20140322272A1 (en) Vaccine
AU2004235815A1 (en) Vaccinating against infectious diseases using proteosomes
CN113876941A (zh) 一种新的快速高效低价的人工合成疫苗的设计和应用
Acevedo et al. Adjuvants: an essential component of neisseria vaccines
HK1118013B (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
MX2009013223A (es) Composicion adyuvante a base de la porina de omps1 de salmonella enterica serovar typhi.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130402